Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Rimmyrah 10 mg/ml solution for injection {equilateral_black_triangle}

Active Ingredient:
ranibizumab
Company:  
Orion Pharma (UK) Limited See contact details
ATC code: 
S01LA04
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials Letters to HCPs Audio/Video
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Rimmyrah CNV educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia
{pdf_link}

Rimmyrah nAMD educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD)
{pdf_link}

Rimmyrah PDR/DMO educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO)
{pdf_link}

Rimmyrah RVO educational materials

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to retinal vein occlusion (RVO)

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Orion Pharma (UK) Limited
Company image
Address
9th Floor, The Blade, Abbey Square, Reading, RG1 3BE, UK
Telephone
+44 (0)1635 520 300
Medical Information e-mail
[email protected]
Out of Hours Telephone
+44 (0)1635 520 300
Adverse event reporting email
[email protected]
Stock Availability
orionukar&[email protected]
WWW
https://www.orionpharma.co.uk